Confluence Wealth Services Inc. Buys 1,376 Shares of Amgen Inc. $AMGN

Confluence Wealth Services Inc. boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 7.8% in the third quarter, HoldingsChannel reports. The institutional investor owned 18,976 shares of the medical research company’s stock after purchasing an additional 1,376 shares during the period. Confluence Wealth Services Inc.’s holdings in Amgen were worth $7,998,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Rational Advisors Inc. grew its stake in Amgen by 13.7% in the 2nd quarter. Rational Advisors Inc. now owns 199 shares of the medical research company’s stock worth $72,000 after acquiring an additional 24 shares in the last quarter. Beacon Financial Advisory LLC raised its stake in shares of Amgen by 2.0% during the second quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company’s stock valued at $461,000 after acquiring an additional 25 shares in the last quarter. James T. Borello RIA raised its stake in shares of Amgen by 13.6% during the third quarter. James T. Borello RIA now owns 209 shares of the medical research company’s stock valued at $88,000 after acquiring an additional 25 shares in the last quarter. Sweeney & Michel LLC raised its stake in shares of Amgen by 0.5% during the third quarter. Sweeney & Michel LLC now owns 5,129 shares of the medical research company’s stock valued at $2,162,000 after acquiring an additional 25 shares in the last quarter. Finally, Legacy Financial Advisors Inc. boosted its holdings in shares of Amgen by 0.8% in the second quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company’s stock valued at $1,234,000 after purchasing an additional 26 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, SVP Rachna Khosla sold 1,252 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,666,817.72. The trade was a 16.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.85% of the stock is owned by company insiders.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New data presented at the American Heart Association’s 2026 Scientific Sessions strengthened the case for earlier and more intensive Repatha treatment. Amgen cited an analysis finding the drug highly cost-effective in high-risk patients without a prior heart attack or stroke, and a long-term analysis associating it with a 29% lower risk of major cardiovascular events in patients with existing cardiovascular disease. These findings could support Repatha’s clinical profile and adoption, although the reported evidence includes an external-control analysis. Read article
• Neutral Sentiment: Investors are watching for ACR conference data on dazodalibep. The coverage frames the results as a test for the program, but the provided reports do not disclose findings, so the clinical and stock impact remains uncertain. Read article
• Neutral Sentiment: Recent coverage also compares Amgen’s dividend income and valuation with Regeneron’s faster growth, while another report says analyst views on Amgen are mixed. Neither item provides a specific new forecast or rating change that clearly shifts the near-term outlook. Read article

Wall Street Analyst Weigh In

Several brokerages recently issued reports on AMGN. Freedom Broker cut Amgen from a “buy” rating to a “hold” rating and increased their price objective for the stock from $450.00 to $470.00 in a research note on Friday, November 6th. Morgan Stanley raised their price objective on Amgen from $359.00 to $410.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 4th. Cantor Fitzgerald lifted their target price on Amgen from $440.00 to $465.00 and gave the company a “neutral” rating in a research report on Wednesday, November 4th. Bank of America upped their target price on Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a report on Wednesday, August 5th. Finally, BMO Capital Markets lowered their target price on Amgen from $450.00 to $415.00 and set a “market perform” rating for the company in a report on Monday, October 12th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eighteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $422.76.

Amgen Stock Performance

NASDAQ AMGN opened at $465.23 on Wednesday. The company has a debt-to-equity ratio of 3.60, a quick ratio of 1.20 and a current ratio of 1.48. The company has a market capitalization of $251.65 billion, a price-to-earnings ratio of 26.99, a price-to-earnings-growth ratio of 3.25 and a beta of 0.43. The company’s 50-day simple moving average is $423.79 and its two-hundred day simple moving average is $379.39. Amgen Inc. has a one year low of $312.39 and a one year high of $483.99.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 EPS for the quarter, beating the consensus estimate of $5.79 by $0.66. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The business had revenue of $10.37 billion during the quarter, compared to analyst estimates of $10.07 billion. During the same quarter in the previous year, the business posted $5.64 EPS. The company’s quarterly revenue was up 8.5% compared to the same quarter last year. Equities analysts forecast that Amgen Inc. will post 23.33 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s dividend payout ratio (DPR) is presently 58.47%.

About Amgen

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.